MALAT1 and neoplasm: In the blocked group, the unlabelled MALAT1 ASO reduced the overall 5’(Cy5.5)-MALAT1 ASO probe uptake, which is significantly lower in the tumour (p=0.002), suggesting the targeted specificity of the 5’(Cy5.5)-MALAT1 ASO probe.